Melbourne, Aug 5, 2010 (ABN Newswire) - The Directors of Benitec Limited (ASX:BLT) (PINK:BNIKF) are pleased to provide this update on the progress of the re-examination of United States Patent 6,573,099 ("'099 Graham Patent"), titled "Control of Gene Expression", currently on appeal at the United States Patent and Trademark Office ("USPTO")'s Board of Patent Appeals and Interferences ("Appeals Board").
A hearing in the re-examination of the '099 Graham Patent was held today at the USPTO in Alexandria, Virginia before a three-judge panel. Arguments were presented by a patent attorney representing CSIRO. Representatives of Benitec were in attendance. As expected, the Appeals Board did not hand down a decision after the hearing. The Company wishes to make it clear that there was no indication from the Appeals Board as to the likely outcome of the hearing, or when a decision will be given. A decision is handed down typically within four months after a hearing.
About Benitec Limited
Benitec Limited (ASX:BLT) (PINK:BNIKF) holds a dominant position in expressed RNA interference (RNAi)-based human therapeutics, with a transformational platform technology supported by a robust and extensive intellectual property portfolio. Benitec is leveraging this platform to develop and build a pipeline of expressed RNAi therapeutics focusing on treatment and alleviation of cancer and infectious disease. With strong global partnerships and committed scientific and clinical investigators, Benitec Ltd aims to deliver a range of novel RNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry.
Contact
Peter French Chief Executive Officer Benitec Limited Mob: +61-412-457-595 Email: pfrench@benitec.com www.benitec.com
ASX:BLT) (
Benitec Limited
){kind=link}